Paliperidonpalmitaat (standaard)

Paliperidone palmitate (Standard) is the analytical standard of Paliperidone palmitate. This product is intended for research and analytical applications. Paliperidone palmitate is an orally effective competitive antagonist of dopamine D2 receptors and 5-hydroxytryptamine 2A (5-HT2A) receptors that can cross the blood-brain barrier. Paliperidone palmitate competitively inhibits the effects of dopamine and 5-hydroxytryptamine by binding to dopamine D2 receptors and 5-HT2A receptors, regulating the balance of the neurotransmitter system and thus exerting antipsychotic activity. Paliperidone palmitate is mainly used in the research field of schizophrenia[1][2][3].

199739-10-1

12352100

5-HT Receptor; Dopamine Receptor; Reference Standards

GPCR/G Protein; Neuronal Signaling; Others

Neurological Disease

O=C(OC1CCCN(C1=NC(C)=C2CCN3CCC(C4=NOC5=C4C=CC(F)=C5)CC3)C2=O)CCCCCCCCCCCCCCC

C39H57FN4O4

664.89

[1]Darville N, et al. The effect of macrophage and angiogenesis inhibition on the drug release and absorption from an intramuscular sustained-release paliperidone palmitate suspension. J Control Release. 2016 May 28;230:95-108.|[2]Pertinez H, et al. Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models. bioRxiv [Preprint]. 2024 Mar 6:2024.03.03.583160.|[3]Kwon JS, et al. Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics. Int Clin Psychopharmacol. 2015;30 (6) :320-328.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-A0019AR/

Reference Standards